866-997-4948(US-Canada Toll Free)

PharmaPoint: Prostate Cancer - France Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Dec 2012

Category :

Cancer

No. of Pages : 169 Pages

PharmaPoint: Prostate Cancer - France Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - France Drug Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

In France, the PSA test and DREs are the most popular diagnostic tests for prostate cancer (EAU, 2012). Routine PSA screening is widely used, although less commonly than in the US. GlobalData’s primary research shows that overall, French prescribing physicians do not plan to change their use of PSA screening in response to the recent USPSTF recommendation against routine screening, nor do they expect referring physicians to change their screening patterns. 

As in most major markets, a diagnosis of prostate cancer in France is confirmed following high PSA levels or other symptoms by multiple core needle biopsies or TRUS, and metastases are diagnosed using bone scans or CT scans (EAU, 2012).

Scope
  • Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in France from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the France Prostate cancer market.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in France
  • Obtain sales forecast from 2012-2022 in France
Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 12

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 13
3.1.3 Prognosis 14
3.1.4 Quality of Life 15
3.2 Symptoms 16

4 Disease Management 17
4.1 Diagnosis and Referral Overview 17
4.2 Treatment Overview 19
4.2.1 Conservative Management Strategies 23
4.2.2 Localized Treatments 24
4.2.3 Hormone Therapy 25
4.2.4 Drug Therapies 27
4.3 France 28
4.3.1 Diagnosis 28
4.3.2 Clinical Practice 28

5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31
5.3 Product Profiles - Major Brands, Hormone Therapies 34
5.3.1 Zoladex (goserelin acetate) 34
5.3.2 Lupron Depot (leuprolide acetate) 37
5.3.3 Eligard (leuprolide acetate) 41
5.3.4 Trelstar (triptorelin acetate) 45
5.3.5 Firmagon (degarelix) 48
5.3.6 Casodex (bicalutamide) 51
5.4 Product Profiles - Major Brands, Chemotherapies 55
5.4.1 Taxotere (docetaxel) 55
5.4.2 Jevtana (cabazitaxel) 58
5.5 Product Profiles - Major Brands, Therapeutic Vaccines 62
5.5.1 Provenge (sipuleucil-T) 62
5.6 Product Profiles - Major Brands, Targeted Therapies 68
5.6.1 Zytiga (abiraterone acetate) 68
5.6.2 Xtandi (enzalutamide) 72
5.7 Product Profiles - Major Brands, Bone Therapies 76
5.7.1 Xgeva (denosumab) 76
5.7.2 Zometa (zoledronic acid) 79
5.8 Other Marketed Hormone and Drug Therapies 82

6 Opportunity and Unmet Need 83
6.1 Overview 83
6.2 Efficacy at Prolonging Overall Survival 84
6.3 Safety 84
6.4 Mitigation of Symptoms 85
6.5 Cost 85
6.6 Convenient Routes of Administration 85
6.7 Accurate Diagnostic Tests and Surveillance Tools 86
6.8 Unmet Needs Gap Analysis 86
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 88

7 Pipeline Assessment 89
7.1 Overview 89
7.2 Promising Drugs in Clinical Development 90
7.2.1 Cabozantinib 92
7.2.2 Custirsen Sodium 96
7.2.3 Sprycel (dasatinib) 101
7.2.4 Yervoy (ipilimumab) 106
7.2.5 Orteronel 111
7.2.6 Alpharadin (radium-223 chloride) 116
7.2.7 Tasquinimod 121
7.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 125

8 Market Outlook 129
8.1 France 129
8.1.1 Forecast 129
8.1.2 Key Events 132
8.1.3 Drivers and Barriers 132

9 Appendix 134
9.1 Bibliography 134
9.2 Abbreviations 147
9.3 Methodology 150
9.4 Forecasting Methodology 150
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 150
9.4.2 Percent Drug-treated Patients 151
9.4.3 Percent Hormone Therapy-Treated Patients 151
9.4.4 Drugs Included in Each Therapeutic Class 151
9.4.5 Launch, Patent and Market Exclusivity Expiry Dates 152
9.4.6 General Pricing Assumptions 154
9.4.7 Individual Drug Assumptions 156
9.4.8 Generic Erosion 165
9.4.9 Pricing of Pipeline Agents 165
9.5 Physicians and Specialists Included in This Study 166
9.6 Survey of Prescribing Physicians 167
9.7 About the Authors 168
9.7.1 Authors 168
9.7.2 Global Head of Healthcare 169
9.8 About GlobalData 170
9.9 Contact Us 170
9.10 Disclaimer 170

List of Table


Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 14
Table 2: Global Variations in Recommendations on Routine PSA Screening 16
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 19
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 21
Table 5: Leading Treatments for Prostate Cancer, 2012 32
Table 6: Product Profile - Zoladex 34
Table 7: Zoladex SWOT Analysis, 2012 36
Table 8: Product Profile - Lupron Depot 37
Table 9: Lupron Depot SWOT Analysis, 2012 39
Table 10: Product Profile - Eligard 41
Table 11: Eligard SWOT Analysis, 2012 43
Table 12: Product Profile - Trelstar 45
Table 13: Trelstar SWOT Analysis, 2012 46
Table 14: Product Profile - Firmagon 47
Table 15: Firmagon SWOT Analysis, 2012 49
Table 16: Product Profile - Casodex 51
Table 17: Casodex SWOT Analysis, 2012 53
Table 18: Product Profile - Taxotere 55
Table 19: Taxotere SWOT Analysis, 2012 57
Table 20: Product Profile - Jevtana 58
Table 21: Jevtana SWOT Analysis, 2012 60
Table 22: Product Profile - Provenge 61
Table 23: Provenge SWOT Analysis, 2012 66
Table 24: Product Profile - Zytiga 68
Table 25: Zytiga SWOT Analysis, 2012 70
Table 26: Product Profile - Xtandi 72
Table 27: Xtandi SWOT Analysis, 2012 74
Table 28: Product Profile - Xgeva 76
Table 29: Xgeva SWOT Analysis, 2012 78
Table 30: Product Profile - Zometa 79
Table 31: Zometa SWOT Analysis, 2012 81
Table 32: Summary of Other Marketed Hormone and Drug Therapies, 2012 81
Table 33: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment 82
Table 34: Overall Unmet Needs, CRPC - Current Level of Attainment 83
Table 35: Clinical Unmet Needs - Gap Analysis, 2012 86
Table 36: Prostate Cancer - Phase III Pipeline, 2012 89
Table 37: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012 89
Table 38: Product Profile - Cabozantinib 91
Table 39: Cabozantinib SWOT Analysis, 2012 95
Table 40: Product Profile - Custirsen Sodium 96
Table 41: Custirsen Sodium SWOT Analysis, 2012 100
Table 42: Product Profile - Sprycel 101
Table 43: Sprycel SWOT Analysis, 2012 104
Table 44: Product Profile - Yervoy 106
Table 45: Yervoy SWOT Analysis, 2012 110
Table 46: Product Profile - Orteronel 111
Table 47: Orteronel SWOT Analysis, 2012 114
Table 48: Product Profile - Alpharadin (radium-223 chloride) 115
Table 49: Alpharadin SWOT Analysis, 2012 119
Table 50: Product Profile - Tasquinimod 120
Table 51: Tasquinimod SWOT Analysis, 2012 123
Table 52: Product Profile - ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 124
Table 53: ProstVac SWOT Analysis, 2012 127
Table 54: Sales Forecasts ($m) for Prostate Cancer in France, 2012-2022 129
Table 55: Key Events Impacting Sales for Prostate Cancer in France, 2012-2022 131
Table 56: Prostate Cancer Market in France - Drivers and Barriers, 2012 131
Table 57: Key Launch Dates 151
Table 58: Key Patent Expiries and Market Exclusivity Expiries 152
Table 59: Physicians Surveyed, By Country 166

List of Chart


Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 20
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022 90
Figure 3: Sales for Prostate Cancer in France by Drug Class, 2012-2022 130

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *